As previously reported, BofA upgraded Gilead to Buy from Neutral with a price target of $95, up from $88, given the belief that Gilead’s accelerating growth and expanding pipeline is “underappreciated by investors.” Gilead is executing well in its core HIV business and in the emerging hematology/oncology, or heme/onc, franchise, says the firm, which thinks shares, which have underperformed year-to-date, “look oversold.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GILD:
- Gilead initiated with a Reduce at HSBC
- MacroGenics achieves $15M milestone related to Gilead nomination
- FDA approves Gilead’s Veklury for COVID-19 in people with hepatic impairment
- Arcus to ‘trade with strength’ after leaked Roche data looked ‘good,’ says BofA
- Gilead announces partial clinical hold on magrolimab studies